lower
respiratori
tract
infect
lrti
lead
infecti
diseas
world
also
fourth
commonest
caus
death
global
account
million
death
worldwid
viral
infect
one
import
caus
lrti
larg
overlap
symptom
clinic
present
bacteri
viral
lrti
antibiot
inappropri
prescrib
patient
viral
infect
may
result
potenti
risk
antimicrobi
resist
correspond
financi
burden
environment
pollut
furthermor
inappropri
prescript
antibiot
even
critic
china
rank
world
frequent
user
antibiot
overus
intraven
antibiot
patient
hospit
lrti
constitut
import
part
inappropri
prescript
antibiot
one
retrospect
studi
teach
hospit
beij
median
durat
intraven
antibiot
day
interquartil
rang
day
among
hospit
individu
mild
moder
communityacquir
pneumonia
cap
diagnost
uncertainti
regard
lack
microbiolog
evid
may
one
import
reason
laboratorydevelop
pcr
test
highli
accur
diagnosi
microbi
aetiolog
turnaround
time
gener
day
howev
experienc
specialist
requir
test
instrument
instal
central
laboratori
filmarray
respiratori
panel
biofir
salt
lake
citi
ut
usa
new
molecular
pointofcar
test
poct
platform
simultan
detect
virus
atyp
pathogen
provid
result
hour
sensit
specif
new
molecular
poct
detect
pathogen
high
sensit
specif
rang
respect
recent
publish
random
control
trial
show
use
filmarray
respiratori
panel
associ
reduct
proport
antibiot
use
among
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
asthma
specul
molecular
poct
detect
virus
might
reduc
durat
antibiot
use
adult
lrti
patient
consid
predomin
overus
intraven
antibiot
china
aim
studi
evalu
whether
combin
poct
routin
realtim
pcr
pathogen
detect
could
reduc
durat
improv
deescal
intraven
antibiot
individu
lrti
compar
routin
realtim
pcr
singlecentr
openlabel
parallel
random
control
studi
took
place
octob
juli
chinaejapan
friendship
hospit
cjfh
beij
china
clinicaltrialsgov
identifi
cjfh
larg
teach
hospit
bed
patient
recruit
gener
ward
depart
pulmonari
critic
care
medicin
depart
tradit
chines
medicin
lung
diseas
depart
infecti
diseas
cjfh
hospit
patient
age
year
preliminarili
diagnos
radiograph
confirm
cap
aecopd
acut
exacerb
bronchiectasi
recruit
day
hospit
patient
exclud
year
old
pregnant
hospitalacquir
pneumonia
lung
tuberculosi
also
exclud
patient
human
immunodefici
viru
infect
haematolog
cancer
solid
tumour
treat
chemotherapi
radiotherapi
previou
month
organ
bone
marrow
transplant
splenectomi
autoimmun
diseas
includ
system
lupu
erythematosu
rheumatoid
arthriti
rheumat
polymyalgia
interstiti
lung
diseas
treat
immunosuppress
therapi
week
addit
patient
condit
may
increas
serum
procalcitonin
level
includ
sever
burn
major
surgic
procedur
major
trauma
longterm
sever
cardiogen
shock
invas
fungal
infect
acut
attack
plasmodium
falciparum
also
exclud
studi
conduct
accord
declar
helsinki
studi
approv
ethic
committe
cjfh
written
inform
consent
obtain
particip
meet
inclus
criteria
random
random
alloc
sequenc
gener
use
spss
softwar
statist
product
servic
solut
ibm
co
ltd
armonk
ny
usa
fix
random
seed
simpl
random
conduct
subsequ
seal
group
alloc
card
envelop
accord
sequenc
number
envelop
open
patient
met
inclus
criteria
sign
inform
consent
alloc
patient
intervent
control
group
accordingli
studi
particip
research
staff
clinic
care
provid
blind
group
alloc
alloc
patient
blind
data
analyst
demograph
clinic
characterist
collect
enrol
studi
commenc
research
personnel
train
take
nasopharyng
swab
oper
filmarray
respiratori
panel
instrument
routin
diagnosi
treatment
microorgan
detect
cap
aecopd
acut
exacerb
bronchiectasi
follow
chines
guidelin
consensu
diseas
intervent
group
research
staff
took
nasopharyng
swab
patient
accord
standard
protocol
within
hour
admiss
sampl
analys
immedi
use
filmarray
respiratori
panel
panel
detect
virus
influenza
viru
influenza
b
viru
respiratori
syncyti
viru
rhinoviru
enteroviru
human
metapneumoviru
parainfluenza
viru
type
coronavirus
adenoviru
two
atyp
pathogen
chlamydia
pneumonia
mycoplasma
pneumonia
one
bacterium
bordetella
pertussi
result
report
explain
physician
via
telephon
send
text
messag
mandatori
feedback
facetofac
commun
day
admiss
intervent
control
group
routin
realtim
pcr
assay
detect
viral
pathogen
includ
influenza
viru
influenza
b
viru
respiratori
syncyti
viru
parainfluenza
viru
adenoviru
epsteinebarr
viru
herp
simplex
viru
human
cytomegaloviru
perform
cjfh
microbiolog
laboratori
sputum
nasopharyng
swab
sampl
see
supplementari
materi
tabl
result
report
explain
physician
obtain
diagnost
test
blood
ga
analysi
c
reactiv
protein
erythrocyt
sediment
rate
procalcitonin
routin
microbiolog
test
prescrib
physician
group
respons
attend
physician
decid
antibiot
administr
includ
moxifloxacin
levofloxacin
type
iiiiii
iv
gener
cephalosporin
carbapenem
blactamaseblactamaseinhibitor
macrolid
penicillin
tetracyclin
deescal
cessat
use
group
without
intervent
research
staff
manag
system
technic
support
framework
antimicrobi
stewardship
establish
china
medic
depart
pharmaci
depart
regularli
assess
use
antibiot
cjfh
data
collect
standard
case
report
form
input
electron
medic
databas
author
assist
primari
outcom
durat
intraven
antibiot
hospit
durat
intraven
antibiot
defin
total
number
calendar
day
one
one
dose
intraven
antibiot
use
secondari
outcom
includ
proport
patient
receiv
intraven
antibiot
proport
patient
antibiot
deescal
within
first
hour
hour
day
length
hospit
stay
cost
intraven
antibiot
cost
hospit
deescal
antibiot
defin
reduct
antibiot
type
chang
intraven
antibiot
oral
antibiot
broadspectrum
antibiot
narrowerspectrum
antibiot
see
supplementari
materi
tabl
cost
hospit
perspect
hospit
deduct
benefit
consist
six
part
includ
laboratori
test
radiat
patholog
blood
biochemistri
test
medic
care
oxygen
therapi
doctor
visit
surgeri
blood
storag
process
drug
medic
materi
cost
see
supplementari
materi
tabl
outcom
measur
discharg
hospit
particip
follow
person
day
train
research
staff
length
hospit
day
six
particip
intervent
group
eight
particip
control
group
lost
follow
advers
outcom
includ
admiss
intens
care
unit
icu
death
hospit
readmiss
within
day
death
within
day
accord
find
branch
et
al
assum
reduct
antibiot
use
intervent
group
would
clinic
signific
estim
patient
would
requir
group
yield
statist
power
detect
reduct
antibiot
use
intervent
group
signific
level
p
assum
studi
particip
would
nonadher
lost
follow
set
total
target
recruit
number
patient
group
data
analys
perform
accord
intentiontotreat
analysi
perprotocol
analysi
exclud
particip
whose
diagnosi
ascertain
lrti
random
withdrawn
refus
nasopharyng
swab
also
perform
baselin
characterist
express
number
proport
median
interquartil
rang
mean
standard
deviat
comparison
made
use
c
test
wilcoxon
ranksum
test
student
ttest
appropri
median
interquartil
rang
primari
outcom
durat
intraven
antibiot
secondari
outcom
includ
length
hospit
stay
cost
intraven
antibiot
cost
hospit
calcul
differ
intervent
control
group
compar
use
wilcoxon
ranksum
test
secondari
outcom
proport
intraven
antibiot
use
deescal
within
first
hour
deescal
hour
day
signific
differ
proport
calcul
c
test
unadjust
odd
ratio
calcul
logist
regress
model
use
look
differ
intervent
control
group
differ
ci
involv
studi
absolut
differ
express
mean
proport
data
analys
perform
use
sa
version
sa
institut
inc
octob
juli
assess
patient
elig
elig
particip
studi
fig
total
patient
randomli
assign
ae
acut
exacerb
aecopd
acut
exacerb
chronic
obstruct
pulmonari
diseas
cap
communityacquir
pneumonia
pneumonia
sever
score
calcul
measur
risk
factor
total
point
criterion
satisfi
confus
defin
abbrevi
mental
test
score
blood
urea
nitrogen
respiratori
rate
bpm
systol
blood
pressur
mmhg
diastol
blood
pressur
mmhg
age
year
data
present
mean
sd
standard
deviat
median
interquartil
rang
continu
variabl
percent
categor
variabl
categor
variabl
compar
use
c
test
continu
variabl
compar
use
wilcoxon
ranksum
test
student
ttest
denomin
number
communityacquir
pneumonia
b
denomin
number
studi
particip
receiv
procalcitonin
test
intervent
group
control
group
includ
intentiontotreat
analysi
patient
intervent
group
patient
control
group
ascertain
lrti
random
withdrawn
refus
nasopharyng
swab
baselin
characterist
studi
particip
intervent
control
group
includ
intentiontotreat
analysi
perprotocol
shown
tabl
supplementari
materi
tabl
respect
patient
intervent
group
test
use
filmarray
respiratori
panel
patient
also
test
use
routin
realtim
pcr
wherea
patient
control
group
test
use
routin
realtim
pcr
viral
pathogen
see
supplementari
materi
tabl
median
durat
intraven
antibiot
treatment
intervent
group
significantli
shorter
control
group
day
day
versu
day
day
differ
day
ci
day
p
tabl
proport
particip
given
intraven
antibiot
high
intervent
control
group
signific
differ
observ
two
group
versu
differ
ci
p
patient
intervent
group
stop
intraven
antibiot
earlier
compar
control
group
p
logrank
test
fig
eight
patient
intervent
group
stop
intraven
antibiot
use
day
receiv
poct
test
result
data
shown
patient
intervent
group
achiev
deescal
within
hour
versu
differ
ci
p
hour
day
versu
differ
ci
p
control
group
perprotocol
analysi
also
show
shorter
intraven
antibiot
treatment
earlier
deescal
intraven
antibiot
intervent
group
compar
control
group
median
length
hospit
stay
intervent
group
significantli
shorter
control
group
day
day
versu
day
day
differ
day
ci
day
p
median
cost
intraven
antibiot
hospit
also
significantli
less
intervent
group
versu
p
versu
p
perprotocol
analysi
also
show
shorter
length
hospit
stay
lower
cost
intraven
antibiot
hospit
intervent
group
compar
control
group
proport
advers
outcom
includ
icu
admiss
death
hospit
readmiss
within
day
death
within
day
found
significantli
differ
intervent
control
group
p
tabl
studi
ad
poct
routin
realtim
pcr
test
shorten
durat
intraven
antibiot
treatment
reduc
length
stay
cost
hospit
improv
earli
deescal
intraven
antibiot
compar
routin
realtim
pcr
assay
hospit
lrti
patient
admiss
icu
fatal
rate
similar
group
efficaci
new
poct
evalu
retrospect
studi
conduct
among
paediatr
patient
random
control
trial
explor
impact
poct
among
adult
small
sampl
one
recent
random
control
trial
rel
larg
sampl
size
evalu
effect
filmarray
respiratori
panel
among
adult
patient
acut
respiratori
ill
howev
half
diagnos
lrti
includ
pneumonia
aecopd
heterogen
studi
popul
includ
asthma
upper
respiratori
infect
limit
extrapol
lrti
advantag
studi
individu
lrti
enrol
exclud
acut
upper
respiratori
infect
noninfecti
respiratori
ill
anoth
advantag
studi
enrol
patient
throughout
four
consecut
season
studi
focus
durat
antibiot
withdraw
antibiot
poct
result
avail
easi
understand
physician
safe
stop
antibiot
soon
know
posit
viral
result
patient
upper
respiratori
infect
asthma
demonstr
studi
brendish
et
al
howev
patient
pneumonia
kind
lrti
chines
physician
refer
local
clinic
guidelin
durat
antibiot
day
cap
day
cap
atyp
pathogen
day
aecopd
day
acut
bronchiectasi
although
difficult
exclud
bacteri
coinfect
knowledg
viral
aetiolog
help
physician
decid
whether
stop
intraven
antibiot
earlier
consid
length
hospit
stay
lrti
patient
directli
relat
durat
intraven
antibiot
final
chose
durat
intraven
antibiot
primari
outcom
median
cost
around
per
hospitalday
patient
lrti
day
less
intraven
antibiot
day
less
hospit
could
save
billion
dollar
china
number
limit
studi
first
singlecentr
studi
result
need
verifi
futur
multicentr
studi
second
cost
filmarray
respiratori
panel
consid
total
cost
hospit
sinc
filmarray
respiratori
panel
commerci
avail
china
posthoc
analysi
indic
cost
hospit
intervent
group
would
lower
least
equal
control
group
filmarray
respiratori
panel
test
cost
less
third
proport
patient
receiv
intraven
antibiot
therapi
high
durat
intraven
antibiot
rel
long
group
extrapol
result
care
interpret
fourth
studi
conduct
gener
ward
data
present
per
cent
categor
variabl
differ
intervent
control
group
compar
use
c
test
logist
regress
model
use
calcul
unadjust
odd
ratio
denomin
number
studi
particip
follow
day
without
includ
patient
icu
effect
poct
need
rigor
evalu
patient
sever
ill
includ
icu
patient
conclus
studi
found
addit
molecular
poct
test
routin
realtim
pcr
test
respiratori
virus
atyp
pathogen
might
help
reduc
intraven
antibiot
use
lrti
patient
without
result
advers
outcom
multicentr
studi
requir
verifi
find
declar
compet
interest
content
manuscript
publish
submit
public
elsewher
abstract
accept
present
at
intern
confer
work
support
nation
scienc
grant
distinguish
young
scholar
grant
number
chines
academi
medic
scienc
innov
fund
medic
scienc
biom
erieux
provid
freeofcharg
filmarray
panel
punch
filmarray
instrument
particip
design
conduct
analysi
studi
bc
conceiv
design
trial
supervis
trial
alloc
staff
full
access
data
studi
take
respons
content
manuscript
sd
dy
particip
recruit
patient
data
acquisit
random
particip
intervent
control
group
accord
random
sequenc
number
done
rs
alloc
patient
finish
hl
yw
xg
gf
perform
data
analysi
sd
bc
xg
draft
revis
manuscript
zx
bl
ensur
qualiti
control
run
environ
filmarray
instrument
author
review
manuscript
contribut
studi
report
whole
progress
author
approv
final
version
manuscript
